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Summary Mitozantrone (Novantrone) has recently been incorporated into a new combination chemotherapy
regimen with mitomycin-C and methotrexate (MMM) against advanced breast cancer. We have compared
MMM (mitozantrone 8 mg m-2 i.v. q 3 weekly, methotrexate 35 mg m-2 i.v. q 3 weekly, mitomycin-C
8 mg m-2 i.v. q 6 weekly) with CMF (cyclophosphamide 100 mg orally, days 1-14, methotrexate 35 mg m-2
i.v., days 1 and 8, 5-FU 1,000 mg i.v., days 1 and 8, q 4 weekly), each regimen with folinic acid rescue, in a
randomised trial. 29/57 evaluable patients treatment with MMM achieved an objective response (51%)
compared with 33/55 treated with CMF (60%). Overall median survival was 16 months for MMM and 12
months for CMF. Subjective toxicity was low for both regimens and the only significant difference was in
incidence of diarrhoea (50% for CMF vs 21% for MMM). Haematological toxicity was similar, leading to
treatment delays and/or dose reductions in 35% patients with CMF vs 43% with MMM. Thrombocytopenia
was significantly increased in MMM (34% vs 14%). No clinical cardiotoxicity was seen, but a significant
reduction in left ventricular ejection fraction occurred in four patients on CMF vs 2 on MMM. MMM is an
active, well tolerated new chemotherapy regimen for advanced/metastatic breast carcinoma with an efficacy
and toxicity spectrum very similar to CMF.
Combination chemotherapy for metastatic breast cancer
commonly achieves tumour response rates of 50-60% in
large series (Aisner et al., 1987; Brambilla et al., 1976; Coates
et al., 1987; Cummings et al., 1985; Tormey et al., 1982;
Hayes & Henderson, 1987) but long term remissions are rare
and one of the main aims of treatment is symptom palliation.
It is therefore important to develop regimens that are not
merely effective, but have low subjective toxicity.
Mitozantrone (Novatrone), an anthracene-dione, is an
active and well tolerated new agent for metastatic breast
cancer with a single agent response of 35% in a series of
previously untreated patients (Stuart-Harris et al., 1984a).
Mitomycin C has likewise been shown to be active and well
tolerated, with a 28% response rate even in previously
treated patients (Van Oosterom et al., 1979). Recently a
combination ofmitozantrone, methotrexate and mitomycin C
(MMM) has been developed and shown to be as active as a
vincristine, adriamycin, cyclophosphamide regimen (VAC)
but less toxic (Judson et al., 1988).
Cyclophosphamide, methotrexate and 5-FU (CMF), in a
variety of schedules, remains one of the most widely used
breast cancer regimens world-wide, with the majority of ran-
domised trials suggesting similar efficacy to Adriamycin-con-
taining regimens but usually with less toxicity (Cummings et
al., 1985; Hayes & Henderson, 1987; Macaulay & Smith,
1986; Moss et al., 1978; Tormey et al., 1982). We therefore
decided to compare MMM with CMF in a randomised trial
of first-line chemotherapy in patients with advanced or
metastatic breast cancer. The design of the trial included
cross-over treatment for non-responding or relapsed patients.
Cumulative cardiotoxicity is less of a problem with mitozan-
trone than with structurally related Adriamycin (Benjamin et
al., 1985; Henderson et al., 1989), but it is nevertheless well
recognised. A component of this trial was therefore serial
monitoring of cardiac function by left ventricular ejection
fraction, whenever possible, for patients on both treatment
arms.
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Patients and methods
Patients
One hundred and twenty patients attending the breast unit at
the Royal Marsden Hospital (Fulham Road), between July
1986 and March 1989 with histologically or cytologically
proven breast cancer and with distant metastases or locally
advanced inoperable disease were entered into this trial.
Details of patient characteristics are given in Table I. The
median age was 55 (range 31-72) years for CMF and 51
(range 29-80) years for MMM. Thirty-seven percent were
pre- or perimenopausal (2 years since last menstrual period)
for CMF and 42% for MMM (see Table I). The majority
had received at least one form of previous endocrine therapy
for advanced disease (70% for CMF and 73% for MMM),
but no patient had received previous chemotherapy for
advanced disease or as adjuvant treatment. Eleven patients
had large primary carcinomas without metastatic spread (6
CMF, 5 MMM), and 28 had metastatic disease at initial
presentation (12 CMF and 16 MMM). For the remainder the
median disease-free interval was 24 months for CMF and 25
months for MMM.
Exclusion criteria were previous cytotoxic chemotherapy,
significant non-metastatic cardiac, renal or hepatic disease, a
life-expectancy of <3 months or unassessable disease as
defined by standard UICC criteria (Hayward et al., 1977).
Table I Patient characteristics
CMF MMM
Patients entered 60 60





Median number of sites (range) 2 (1-5) 2 (1-5)
Previous endocrine therapy for advanced 42 44
disease
Median disease free interval (months) 24 25
Primary medical treatment 6 5
Presenting with metastatic disease 12 16
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Randomisation and treatment schedules
Patients were randomised to receive MMM or CMF as first
line treatment using a permutating block technique. There
was no stratification. Treatment was usually given on an










repeating every 21 days
CMF
Cyclophosphamide 100 mg orally
Methotrexate 35 mg m-2 i.v.
(max. 50 mg)
5 Fluorouracil 1 G i.v.
repeating every 28 days
day 1
day 1
day 1 - alternate
courses only
days I to 14
days 1 and 8
days 1 and 8
Initially prophylactic folinic acid rescue was not given, but
a significant number of patients complained of low grade
(WHO Grade I-II) but troublesome mucositis. Therefore,
after February 1987, folinic (15 mg orally 6 h for 4 doses,
commencing 24 h after chemotherapy) was prescribed pro-
phylactically for the subsequent 81 patients.
Treatment duration and cross-over
Patients who achieved an objective response as defined by
standard UICC criteria (Hayward et al., 1977) (see below),
continued to six courses and were then randomised to stop
treatment or continue to 12 courses as part of a separate
maintenance chemotherapy trial. Patients who developed
progressive disease or had stable disease, but had failed to
achieve symptomatic relief after two courses were changed to
a crossover regimen excluding methotrexate (i.e. MM or CF),
if this were clinically appropriate. Likewise responding
patients received the crossover regimen at relapse.
Dose modification
Treatment was only given if the peripheral white blood count
(WBC) was > 3.0 x 1091-' and platelet count >100 x 109
1-'. If the WBC <3.0 x 109 1' or platelet count <100 x
1091- at the start of the second or subsequent courses,
treatment was delayed until these parameters had recovered.
After two delays the dose of all drugs was reduced by 25%
and if two further delays occurred, reduction to 50% of the
original dose was made. Further delays led to the treatment
being stopped. If any patient developed a neutropenic infec-
tion the dose of all drugs in subsequent courses were reduced
by 25%.
Anti-emetics
All patients received prophylactic anti-emetic cover usually
comprising metoclopramide 20mg i.v. and dexamethasone
8 mg i.v. or orally pre-chemotherapy. If nausea or vomiting
occurred oral metoclopramide 20 mg, 4-6 hourly was con-
tinued after the initial injection and if necessary lorazepam
I mg, 4-6 hourly was added as a third agent.
Investigations and response assessment
A peripheral full blood count, plasma urea, electrolytes and
serum liver function tests were carried out before each treat-
ment. Specific investigations to document and assess tumour
sites including chest X-ray, radiological skeletal survey and
CT scanning were carried out prior to treatment, after two
courses and at the end of treatment (completion of six
courses or progression of disease). Palpable lesions were
assessed at each course of treatment and earlier assessment of
other disease sites was carried out if clinically indicated.
Response was assessed according to standard UICC criteria
(Hayward et al., 1977). Life tables were drawn using the
Kaplan Meier method and comparisons were performed
using the log rank test (Peto et al., 1977). Groups were
compared using the chi-squared test and the Mann Whitney
test for trend.
Toxicity for each course of treatment was assessed using
standard WHO criteria (WHO Offset Publication, 1979) and
recorded at each visit on a standardised Breast Unit check
list.
Cardiotoxicity
Cardiac function was monitored in all patients entered after
October 1986. An ECG and assessment of left ventricular
ejection fraction at rest and on exercise (LVEF) were per-
formed prior to treatment, at crossover (i.e. disease progres-
sion) and at completion of treatment. These assessments were
continued at 6-monthly intervals during follow up. LVEF
was assessed by gated pool scanning following in vivo labell-
ing of red cells with 9'Technecium, a technique commonly
used in the assessment of antracycline induced cardiotoxicity
(Kennedy et al., 1978).
One hundred and seven patients were eligible for this part
of the protocol but only 75 commenced the study. Fifteen
patients were felt to be too unwell to complete the stress
phase of the study, 16 patients were not asked to enter
because of transport problems, and one patient suffered a




One hundred and twelve patients are evaluable for response
(55 CMF, 57 MMM). Eight patients initially randomised
were deemed inevaluable for response because of: (i) treat-
ment toxicity (1 CMF); (ii) unwillingness to continue (2
CMF, 1 MMM); or (iii) early death during first course of
treatment (2 CMF, 2 MMM). Twenty-nine patients on
MMM achieved an objective response (51%; 95% confidence
limits 38-64%), compared with 33 receiving CMF (60%;
confidence limits 47-73%). Of these responders, 2 (4%) in
each group achieved a complete remission. Objective results
are summarised in Table II.
Response, duration, survival
No significant differences between the two groups were found
for median response duration (7 months: MMM and CMF,
Figure 1), time to progression (CMF 5 months, MMM 6
months, Figure 2) and overall survival (CMF 12 months,
MMM 16 months, Figure 3). Responses by site of disease are
given in Table III.
Crossover responses
Fifty-two patients have crossed over and 48 are evaluable for
response to second line therapy. These results are shown in
Table IV and have been displayed according to response to




Complete response 2 (4) 2 (4)
Partial response 31 (56) 27 (47)
Overall response (with 95% confidence 60% 51%
limits) (47-73%) (38-64%)
No change 13 (24) 17 (30)
Progressive disease 9 11796 D.I. JODRELL et al.
Duration of response: CMF vs MMM
2
Time since start of treatment (years)
Duration of response: CMF( ) vs. MMM








Table III Response by site of disease
CMF(%) MMM(%)
'Local 17/25 (68) 19/32 (60)
Soft tissue 10/12 (83) 8/11 (73)
Lung 7/14 (50) 7/19 (37)
Liver 6/9 (67) 7/14 (50)
Bone 4/14 (29) 1/14 (7)
first line treatment. Eight of 23 MMM patients subsequently
responded to cross-over cyclophosphamide/5 FU (35%);
seven of these had previously responded to MMM. One out
of 25 CMF patients subsequently responded to cross-over
mitozantrone/mitomycin C (4%); 12 of these had previously
responded to CMF.
Toxicity
In general CMF and MMM were well tolerated with a low
incidence of severe toxicity (WHO grades III and IV) for
both regimens. Details of subjective toxicity are given in
Table V. The only significant difference was the incidence of
diarrhoea with CMF (50% all grades compared with 21%
for MMM, P<0.001). 5 FU doses were reduced in three
patients (two by 25%, one by 75%) with an improvement in
symptoms, allowing treatment to continue. As shown in
Table V the incidence of mucositis dropped significantly
(P = 0.05 CMF, P = 0.02 MMM) after the introduction of
folinic acid rescue. Significant alopecia requiring a wig was
uncommon, occurring in only 7% of patients for both
regimens.
Haematological toxicity leading to delays (i) in treatment
and/or (ii) >25% dose reductions occurred in (i) 15% and
(ii) 20% ofpatients treated with CMF (total 35%) compared
with (i) 18% and (ii) 21% treated with MMM (total 43%)
(difference not significant, P=0.2). Details are shown in
Table VI. Thrombocytopenia (<1I00 x I01'I') occurred in
34% patients receiving MMM compared with 14% CMF










Time since start of treatment (years)
Progression free survival: CMF ( ~) vs. MMM
Survival from randomisation: CMF vs MMM
1 2
Time since start of treatment (years)
Figure 3 Survival from randomisation: CMF ( ) vs.
MMM (---).
Table IV Crossover responses by initial response to firstline
therapy
Response to MMM:
CR PR NC PD
Cyclophosphamide & 5 FU PR 8 =7 1
(23 evaluable patients) NC 7 = 2 2 3
3 NE incomplete data PD 8 =3 2 3
Response to CMF:-
CR PR NC PD
Mitomycin C & mitozantrone PR 1 =
(25 evaluable patients) NC 12 = 5 4 2
I NE incomplete data PD 12 = 2 7 2 2
Overall response: CF =35% (95% confidence limits 15-56%);
MM =4% (95% confidence limits 0- 12%). The basic response rate
difference is significant (P = <0.01) but inclusion of 'no change' and
PD, and analysis by Mann Whitney test for trend gives P = 0.07.
NE = not evaluable; CR = complete response; PR = partial response;
NC = no change; PD = progressive disease.
Table V Subjective toxicity (expressed as %)
CMF MMM
WHO grade 1-2 3-4 1-2 3-4
Alopecia 67 7 58 7
Nausea and vomiting 70 6 62 11
Mucositis - pre Feb '87* 63 5 67 -
-postFeb'87 38 2 33 2
Diarrhoea** 43 7 19 2
Lethargy 19 2 16 -
Infection 8 3 18 3
*Feb '87 - prophylactic folinic acid commenced; "*Difference is
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Table VI Haematological toxicity (expressed as %)
WHO grade
1 2 3 4
Haemoglobin
CMF 25 20 4 -
MMM 30 28 5 - NS
WBC
CMF 25 29 15 7
MMM 19 32 23 2 NS
Platelets
CMF 5 - 5 4
MMM 9 11 9 5 P= 0.03
NS = not significant.
WHO Grade III or IV leucopenia (WBC <2.0 + IO' 1')
occurred in 25% of patients receiving MMM and 22% of
those receiving CMF. There was one death associated with
leucopenia in a patient receiving CMF.
Cardiotoxicity Of the 75 patients who commenced the car-
diac scan protocol only 45 (60%) had a second (post initial
treatment scan). The reasons for the failure to complete these
studies included poor clinical condition (27%), refusal (3%),
depression (1%), chest wall radiotherapy (3%) and difficulty
in travelling (7%).
Six of these 45 (13%) were noted to have a significant
reduction (> 10%) in LVEF after initial treatment. Surpris-
ingly, four of these patients had been treated with CMF. One
of the two patients with reduction in LVEF whilst receiving
MMM had an abnormal ECG at the start of treatment (left
axis deviation) and neither patient suffered symptoms of
cardiac failure. Histological examination of myocardial tissue
was not undertaken.
Discussion
The combination MMM has already been reported as having
a response rate and survival as good as that for vincristine,
anthracycline and cyclophosphamide combination; in that
trial the absence of vincristine- and anthracycline-related pro-
blems resulted in less overall toxicity (Judson et al., 1988).
This trial confirms that MMM is an active and well tolerated
new chemotherapy regimen for advanced breast cancer with
an efficacy, in terms of response rate and survival, and a
toxicity spectrum very similar to a standard CMF regimen. It
is, however at present considerably more expensive: currently
in the UK a single course of MMM costs around £120
compared with £13.50 for CMF.
It must be noted that the doses of our CMF combination
were lower than those reported in some other studies (Cum-
mings et al., 1985; Aisner et al., 1987; Coates et al., 1987),
but not all: the dose rate was in fact slightly higher than the
higher of two dose levels of CMF compared in a recent trial
(Tannock et al., 1988). In addition treatment actually deliver-
ed is often less than treatment planned: in a classic adjuvant
CMF trial only 17% of patients received the intended dose
(Bonadonna et al., 1981). Our choice of dose was based on
what we have found to be realistically achievable in clinical
practice, and this was borne out by our results. Seventy-six
percent ofpatients on CMF had some degree of neutropenia,
including 22% with severe neutropenia. Sixty-eight percent
had mucositis before we introduced folinic acid rescue, and
50% diarrhoea. More than one third of patients required a
dose reduction or treatment delay. Such toxicity might seem
relatively modest for a potentially curative regimen, but is
considerable when the main aim of treatment is palliation as
here. Furthermore, the response rate was in the same range
as that achieved with higher dose studies.
Whilst the initial response rates are similar, a difference
was seen in the crossover responses with only one patient
responding to MM, having received CMF previously. How-
ever, the clinical significance of this is unclear, since numbers
are small and mitozantrone has been shown to be active as a
single agent in patients previously treatment with CMF
(Stuart-Harris, 1984a).
Despite the low incidence of severe subjective toxicity and
significant alopecia with MMM, it is nevertheless important
to note that significant haematological toxicity did occur,
with 43% of patients requiring treatment delay or dose
reduction. This occurred despite a significant dose reduction
compared with single agent studies: mitozantrone was reduc-
ed from 12-14mgm2 (Stuart-Harris et al., 1984a) to 8 mg
m-2, and mitomycin-C from 12mgm-2 (Van Oosterom et
al., 1979) to 8 mg m-2. Haematological toxicity, as discussed
above, was also a problem with CMF, causing treatment
delay or dose reduction in 35% ofpatients and including one
neutropenic death. In addition MMM was more likely to
cause thrombocytopenia than CMF (34% compared with
14%, P=0.03).
The results of our cardiotoxicity study were unexpected.
Mitozantrone has established clinical cardiotoxicity (Benja-
min et al., 1985; Henderson et al., 1989; Stuart-Harris et al.,
1984b) although the drug appears to be significantly less
clinically cardiotoxic than other anthracyclines (Henderson et
al., 1989). In the absence of predisposing factor, mitozan-
trone-induced cardiotoxicity is unusual at cumulative doses
below 160 mg m-2 (Posner et al., 1985), well above the
cumulative dose here of 48mgm-2 after six courses. No
evidence of clinical cardiac failure was seen in this study.
Four out of six patients who had significant reductions in
their ventricular ejection fraction turned out to have been
treated with CMF rather than MMM. This suggests that
deteriorating cardiac function may relate to advanced meta-
static cancer rather than directly to therapies, and casts some
doubt on studies commenting on mitozantrone- and anthra-
cycline-related cardiotoxicity using this technique alone.
There is continuing debate on what constitutes the most
effective chemotherapy for metastatic breast cancer. The
overall response rates and survival for both arms of this trial
were similar to those reported in large series using both CMF
and Adriamycin-containing regimens (Coates et al., 1987;
Cummings et al., 1985; Hayes & Henderson, 1987; Macaulay
& Smith, 1986; Smalley et al., 1983). Occasionally, better
results have been reported, particularly with Adriamycin-
containing regimens (Aisner et al., 1987), but these have not
been confirmed by other studies. Comparisons of results
between different trials are difficult because of potential vari-
ations in the selection criteria used for patient entry. In
particular, as recently emphasised by Tannock et al. (1988)
policies differing between Units on the timing of chemo-
therapy intervention in the natural history of metastatic
breast cancer will influence survival from the start of treat-
ment quite independently of therapeutic effect.
Our conclusions from our own trial and from a compari-
son with these other studies is that MMM now joins CMF as
an effective and useful palliative treatment for metastatic
breast cancer with important advantages over Adriamycin-
containing regimens in terms of better patient tolerance.
We wish to thank Sister Diane Button and Mrs Julia Holborn for
their help in preparing this manuscript.
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